ClinicalTrials.gg
CompletedNCT06395571Updated May 2, 2024

GI Symptoms in Infants Fed GMF or CMF

An interventional study of Goat milk-based infant formula and Cow's milk-based infant formula in Gastrointestinal Diseases and Infant Nutrition Disorders, sponsored by Ausnutria Hyproca B.V.. Completed at 1 site in Brazil. Open to participants aged 3 Months to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Ausnutria Hyproca B.V. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Apr 2019, registered Apr 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
3 Months to 12 Months
Sex
All
01

Study summary

The aim of this study was to assess common gastrointestinal symptoms in healthy Brazilian infants receiving goat milk-based infant formula (GMF) compared to cow's milk-based infant formula (CMF) during a 24 week intervention.

Read the detailed description

Anecdotal evidence shows that the use of goat milk-based infant formula decreases discomfort of infants with cow's milk related symptoms. In this double-blind, randomized controlled trial, gastrointestinal comfort in infants fed goat milk-based infant formula (GMF) or cow's milk-based infant formula (CMF) was studied.

Fifty-six healthy infants aged 3-12 months were followed for 24 weeks. Stool consistency, regurgitation frequency and crying duration were measured weekly using an adapted version of the Cow's Milk-related Symptom Score (CoMiSS®) where only the items for these scores were used. Blood hemoglobin levels were measured at the start and at the end of the intervention.

02

Conditions studied

  • Gastrointestinal Diseases
  • Infant Nutrition Disorders

Keywords

  • goat milk-based infant formula
  • infant formula
  • gastrointestinal comfort
  • infant nutrition
03

In context

Gastrointestinal Diseases

639 studies on the registry are indexed under Gastrointestinal Diseases; 126 are open to participants now.

This study's enrollment of 56 is below the median of 77 across 428 interventional studies indexed under Gastrointestinal Diseases.

Browse Gastrointestinal Diseases studies →

Lead sponsor

Ausnutria Hyproca B.V. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • gestational age 37-42 weeks
  • 3-12 months old at enrollment
  • should have consumed cow's milk-based products during the 48 hours prior to the baseline visit to exclude cow's milk allergic infants

Exclusion criteria

Exclusion Criteria:

  • metabolic or chronic disease or congenital malformation, serious concurrent illness that would interfere with study treatment, (i.e. sepsis, pneumonia with respiratory failure, cardiac failure)
  • infant's parent(s) or primary caregiver(s) diagnosed with major depression
  • infant's weight for length at baseline >\|3\| z-score indexes according to WHO criteria
  • infants enrolled in another interventional clinical research study
  • infants diagnosed with cow's milk allergies
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Goat milk-based infant formula

    Experimental group receives goat milk-based formula for 24 weeks

    Dietary Supplement: Goat milk-based infant formula

  • Active comparator
    Cow's milk-based infant formula

    Control group receives cow's milk-based formula for 24 weeks

    Dietary Supplement: Cow's milk-based infant formula

Interventions

  • Dietary supplementGoat milk-based infant formula

    Goat milk-based infant formula fed at age appropriate quantities for 24 weeks

  • Dietary supplementCow's milk-based infant formula

    Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks

06

What researchers measure

Primary outcomes

  1. Gastrointestinal symptoms

    Stool consistency, regurgitation frequency and crying duration as measured by an adapted Cow's Milk-related Symptom Score®, where a higher score indicates more severe symptoms.

    Time frame: 24 weeks, measured weekly

Secondary outcomes

  1. Blood hemoglobin levels

    Blood hemoglobin levels before and after intervention

    Time frame: 24 weeks, measured at start and end

  2. WHO z-score of weight-for-age

    Weight measured to the nearest 5.0 grams with clothes and diaper removed.

    Time frame: 24 weeks, measured monthly

  3. WHO z-score of length-for-age

    Body length without shoes, measured lying down to the nearest centimeter with a neonatometer.

    Time frame: 24 weeks, measured monthly

  4. WHO z-score of head circumference-for-age

    Head circumference measured with flexible non-stretching tape to the nearest centimeter.

    Time frame: 24 weeks, measured monthly

  5. WHO z-score of weight-for-length

    Weight and length measured as described above combined.

    Time frame: 24 weeks, measured monthly

07

Study locations

1 site
  • Daycare center
    Salvador, Estado de Bahia, Brazil
08

References and documents

Publications

  • Maximino P, van Lee L, Meijer-Krommenhoek YN, van der Zee L, da Costa Ribeiro Junior H. Common gastrointestinal symptoms in healthy infants receiving goat milk-based formula or cow's milk-based formula: a double-blind, randomized, controlled trial. BMC Pediatr. 2024 Nov 20;24(1):753. doi: 10.1186/s12887-024-05214-y. PubMed 39567910 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Oct 2019, 5 months.

Of 176 interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 42. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 2, 2024
StartActual
Apr 17, 2019
Primary completionActual
Oct 6, 2019
CompletionActual
Oct 6, 2019
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06395571
Lead sponsor
Ausnutria Hyproca B.V.
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Apr 17, 2019
Primary completion
Oct 6, 2019
Completion
Oct 6, 2019
Last update
May 2, 2024

Study contacts

Hugo da Costa Ribeiro, Dr.
principal investigator · Hospital Professor Edgard Santos, Federal University of Bahia, Salvador, Brazil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion